Suchergebnisse - "rucaparib"

PubPharm (404)

21

Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis

enthalten in: European urology oncology | 2023

von Fazekas, T. | Széles, �. | Teutsch, B. | +8

22

Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer : A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

enthalten in: Current computer-aided drug design | 2023

von Chen, J. | Wu, X. | Wang, H. | +3

23

A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Pook, D. | Geynisman, D. | Carles, J. | +18

24

Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial

enthalten in: Gynecologic oncology | 2023

von Peipert, J. | Goble, S. | Isaacson, J. | +5

25

Rucaparib for PARP inhibitor-pretreated ovarian cancer : A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program

enthalten in: Gynecologic oncology reports | 2023

von Yubero, A. | Estévez, P. | Barquín, A. | +8

26

A real-world disproportionality analysis of Rucaparib : Post-marketing Pharmacovigilance Data

enthalten in: BMC cancer | 2023

von Zhang, Q. | Ding, Y. | Shu, Y. | +1

27

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data

enthalten in: BMC cancer | 2023

von Zhang, Q. | Ding, Y. | Shu, Y. | +1

28

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data

enthalten in: BMC cancer | 2023

von Zhang, Q. | Ding, Y. | Shu, Y. | +1

29

Safety of PARP inhibitors as maintenance therapy in ovarian cancer

enthalten in: Expert opinion on drug safety | 2023

von Cecere, S. | Casartelli, C. | Forte, M. | +2

30

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot : Development, Validation and Clinical Validation for Therapeutic Drug Monitoring

enthalten in: Pharmaceutics | 2023

von Canil, G. | Orleni, M. | Posocco, B. | +7